What are peoples views on BIEL

9332EDWARD

Im fairly new to investing and have been looking at this stock for a while now, but have not invested yet..


Just wondering does anyone have any views on this stock..

Thanks in advance..

Idu

Why dont you tell us your views on it? For those of us who have no idea what it is

pirelli

9332EDWARD wrote: »

Im fairly new to investing and have been looking at this stock for a while now, but have not invested yet..


Just wondering does anyone have any views on this stock..

Thanks in advance..

Its a high risk small cap pharma stock that has no real income. It really is up to how confident you are it will pass FDA approval. The type of product it has though looks quite straight forward.

On the downside look at ctic it has just had a problem with the FDA.

This look at BioElectronics Corporation (BIEL) is a follow-up to our August 12th look, with which we pointed out that BIEL shares were approaching the tip of a wedge and were going to be forced out - one way or another.

Initially (for about a day) BioElectronics hinted at an upside move. The next day, and every day since then, BIEL was sliding lower. The bleeding may have stopped, however, at a major support level. The bar gave us a reversal clue as well.

One of the other ideas we mentioned on the 12th regarding the chart of BioElectronics Corporation was the Fibonacci retracement lines; the one of most interest was the 38.2% retracement at $0.059. Care to guess where BIEL closed yesterday after hitting a low of $0.055? It ended the day at $0.61, and is inching higher today. The Fib retracement may have sufficiently relieved any bearish pressure.

Yesterday's bar from the BioElectronics Corporation chart was also a pretty tall doji, indicating that the bears and bulls reached a volatile equilibrium, and the sellers handed the reigns over to the buyers. This could be an optimal short-term entry point.

pirelli

CTIC has just plummeted , IDU will be delighted, but that is the risk with small cap pharma stocks they depend entirely on their phase tests results and FDA responses. Any negative result or negative FDA response such as a delay will have a detrimental effect on the stock.



Cell Therapeutics (Nasdaq: CTIC) said today that the FDA has denied
the drugmaker its request for a priority review of its experimental
cancer drug Pixantrone.
Pixantrone now faces a standard 10-month review, instead of the six-
month review usually granted under a priority review.
A priority review is often only granted to new treatments when no
drugs are available for a particular illness. However, Pixantrone's
rivals may make it to the market before or around the time of the FDA
action.
CTIC expects a Pixantrone action date by the FDA in summer 2010.

Idu

pirelli wrote: »

CTIC has just plummeted , IDU will be delighted,

Why would I be delighted about that?

pirelli

Idu wrote: »

Why would I be delighted about that?

CTIC was distracting you so i would have thought you might be happy to see the back of it... at least for a few months until this hard to kill stock gets a drug approval.